Special Report: Rare Disease and Orphan Disease Drug Development
FierceBiotech Special Report: Rare and Orphan Disease Drug Development
There’s a reason rare diseases are called orphans. Small disease populations represent small customer bases. Given that it can cost billions of dollars to bring a new drug to market, pharmaceutical companies have traditionally tended to shy away from such conditions in favor of more common indications.
Buoyed by financial incentives, dedicated regulatory paths, and highly engaged patient advocates, drug developers are devoting considerable resources to rare indications, and adopting some clever science to bring those orphan diseases home.
Companies like Pfizer, GlaxoSmithKline, and Shire Pharmaceuticals have established units dedicated to rare disease drug development. Last year Sanofi scored one of the largest rare diseases pipelines and businesses in the world via its acquisition of Genzyme for $20.1 billion.
To read more about the challenges and opportunities associated with bringing drugs for rare diseases to market, download the complete report today.
| Friday, October 9th | 11:00am ET / 8:00am PT | Presented by: PAREXEL
Clinical trial enrolment continues to be a challenge for the pharmaceutical industry. We will look at how utilizing a Functional Service Model can allow you access to experts that can develop, execute, and analyze your recruitment (and retention) strategies to achieve enrolment success. Register Now!
FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!